Evidence map›Paper›PMID 41503777›Full record

ArticleHuman vaccines & immunotherapeutics2025

Association between immune-related adverse events and prognosis in immune checkpoint inhibitor therapy: A bibliometric and visual analysis.

Jun Zhao, Xianghua Quan, Yu Liang, Beibei Ni, Xiaomin Xing, Guangwei Liu

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jun ZhaoDepartment of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Xianghua QuanDepartment of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Yu LiangDepartment of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Beibei NiDepartment of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Xiaomin XingDepartment of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Guangwei LiuDepartment of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the gradual improvement in tumor immunotherapy, the incidence of immune-related adverse events (irAEs) has increased. However, according to current research, the relationship between irAEs and prognosis remains a contentious issue. This study used bibliometrics research to investigate hotspots and future trends on the relationship between irAEs and prognosis and to serve as a resource for researchers in this field. In the core literature database of Web of Science, the keywords immune checkpoint inhibitors(ICIs), immune-related adverse events, prognosis were used to search for the articles and reviews in the field of irAEs and prognosis. Set the time parameter to January 2007 to December 2023. Visualization analysis software CiteSpace 6.1.R6, VOSviewer1.6.18 and Carrots2 were used to conduct quantitative statistical and visual research on the author, institution, country, keyword, publication, cited literature, research status, research hotspots and development trends of the relevant research. The analytic research was based on original articles and reviews. 724 articles from 308 countries led by China(147),the United States(131), and Japan(105) were included. The most popular tumor type is melanoma, small-cell lung cancer, and renal cell carcinoma. The focus topics in this field encompass "Myasthenia gravis," "neurotoxicity," "liver damage," "head and neck adverse events," "colitis," and "skin adverse events." This study has provided a valuable reference for future research in this field. Combination therapy, predictive biomarkers, patients' preexisting conditions, glucocorticoids, prognostic indicators, ICI rechallenge, and other topics could become research hotspots which will help us to identify useful information from complex big data and provide a basis for precise medicine for immune checkpoint inhibitor therapy.

Indexed as

BibliometricsDrug-Related Side Effects and Adverse ReactionsImmune Checkpoint InhibitorsImmunotherapyNeoplasmsHumansPrognosisImmune Checkpoint InhibitorsbibliometricscancerImmune check point inhibitorsimmune-related adverse eventsprognosisvisual analysis

Identifiers

PMID41503777
PMCPMC12915871

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.